EQ
Equillium IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$121.39M
P/E Ratio
—
EPS
$-0.39
Beta
1.74
52W High
$2.70
52W Low
$0.27
50-Day MA
$1.85
200-Day MA
$1.32
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
1.53
PEG Ratio
—
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical needs. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | $4.39M |
| Gross Profit (TTM) | $4.39M |
| EBITDA | $-23.52M |
| Operating Margin | 0.00% |
| Return on Equity | -94.00% |
| Return on Assets | -51.40% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $0.47 |
| Price-to-Book | 3.76 |
| Price-to-Sales (TTM) | 20.22 |
| EV/Revenue | 21.19 |
| EV/EBITDA | 0.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -52.30% |
| Shares Outstanding | $63.23M |
| Float | $31.50M |
| % Insiders | 20.11% |
| % Institutions | 60.89% |
Historical Volatility
HV 10-Day
118.75%
HV 20-Day
100.34%
HV 30-Day
110.06%
HV 60-Day
91.60%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($6.40 target)
3
Buy1
HoldData last updated: 4/15/2026